Sotera Health(US:SHC)2025-11-04 14:00Financial Performance Highlights - Net revenues increased by 9.1% (8.0% on a constant currency basis) to $311312000 in Q3 2025 compared to $285468000 in Q3 2024[31] - Adjusted EBITDA increased by 12.2% (11.2% on a constant currency basis) to $164000000 in Q3 2025 compared to $146000000 in Q3 2024[31] - Adjusted EBITDA margin increased by 147 basis points to 52.7% in Q3 2025[25, 31] - Adjusted EPS increased by $0.09 to $0.26 in Q3 2025[25, 31] - Net Leverage Ratio improved to 3.3x as of September 30, 2025, compared to 3.7x as of December 31, 2024[29, 44] Segment Performance - Sterigenics' revenue increased by 9.8% (8.4% on a constant currency basis) in Q3 2025[33] - Nordion's revenue increased by 22.4% (23.6% on a constant currency basis) in Q3 2025[36] - Nelson Labs' revenue decreased by 5.0% (-6.4% on a constant currency basis) in Q3 2025[39] Liquidity and Capital Deployment - Strong liquidity position of $891000000 as of September 30, 2025, with no outstanding borrowings on the revolving line of credit[29, 43] - Executed $75000000 Term Loan repayment in Q3 2025[29] 2025 Outlook - Full-year 2025 net revenue growth is expected to be between 4.5% and 6.0%[52] - Full-year 2025 Adjusted EBITDA growth is expected to be between 6.75% and 7.75%[52]